Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MISSION Therapeutics Receives £20m Series B Funding

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
Financing round will enable MISSION to advance its programmes for the treatment of cancers.

Imperial Innovations Group plc has increased its support for MISSION Therapeutics by committing £4.5m of a £20m funding round. Innovations had previously participated in a £6m round for MISSION in August 2011.

MISSION is a biotechnology company developing drugs that target a cell’s response to DNA damage. Innovations is joined in the round by new investor Pfizer Venture Investments and other existing investors Sofinnova Partners, SR One and Roche Venture Fund.

The financing round will enable MISSION to advance its lead programmes for the treatment of various genetically defined cancers, through preclinical development and to exploit further the potential of its novel technology platform.

MISSION was formed to exploit advances in the biology of the DNA damage response for the discovery of new classes of therapeutic agents with novel mechanisms of action.

Utilizing fundamental research principally generated in the laboratory of Professor Stephen Jackson, MISSION has progressed several small molecule discovery programmes focused on key enzymes in the ubiquitin pathway to selectively target difficult-to-treat cancers.

Rob Woodman, Director of Healthcare Investments at Innovations and a non-executive director on MISSION’s board, said: “MISSION’s strong leadership team has made excellent progress in translating fundamental knowledge from the laboratory into a strong drug discovery platform. The VC arms of three of the world’s top five pharmaceutical companies are now supporting MISSION with SR One, Roche Ventures and now Pfizer Ventures investing alongside Innovations, and this is a great endorsement of our model of building companies based on world-class science.”

Michael Moore, Executive Chairman, MISSION, said: “This timely investment will significantly enhance our internal capabilities and strategic goals. It will enable us to build on the Company’s achievements since inception two years ago, strengthen our management team and advance our lead compounds towards the clinic.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Innovations Invests in £17 Million Funding Round for Portfolio Company, Cell Medica
Cell Medica continue to develop immune reconstitution cell therapies in Europe and to launch new operations in US.
Tuesday, July 24, 2012
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
The Epigenetic Influences of Chronic Pain
Researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Mothers Obesity Could be Passed on in mtDNA
Obesity can predispose offspring in multiple generations to metabolic problems.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Naked Mole Rat Exhibits “Extraordinary” Cancer Resistance
Scientists are getting closer to understanding the anti-cancer mechanism of the naked mole rat by making induced pluripotent stem cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!